mutLBSgeneDB |
Gene summary for ATAD2 |
![]() |
Basic gene Info. | Gene symbol | ATAD2 |
Gene name | ATPase family, AAA domain containing 2 | |
Synonyms | ANCCA|CT137|PRO2000 | |
Cytomap | UCSC genome browser: 8q24.13 | |
Type of gene | protein-coding | |
RefGenes | NM_014109.3, | |
Description | AAA nuclear coregulator cancer-associated proteinATPase family AAA domain-containing protein 2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 611941 | |
HGNC : HGNC | ||
Ensembl : ENSG00000156802 | ||
HPRD : 10678 | ||
Vega : OTTHUMG00000165090 | ||
Protein | UniProt: Q6PL18 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ATAD2 | |
BioGPS: 29028 | ||
Pathway | NCI Pathway Interaction Database: ATAD2 | |
KEGG: ATAD2 | ||
REACTOME: ATAD2 | ||
Pathway Commons: ATAD2 | ||
Context | iHOP: ATAD2 | |
ligand binding site mutation search in PubMed: ATAD2 | ||
UCL Cancer Institute: ATAD2 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID | GO:0006200 | ATP catabolic process | 17998543 | GO:0045893 | positive regulation of transcription, DNA-templated | 17998543 |
Top |
Ligand binding site mutations for ATAD2 |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | T1084,A1080 | R1082T | BRCA | 1 | D1014 | D1014N | COAD | 1 | D1020 | D1020H | HNSC | 1 | E1017 | E1017K | HNSC | 1 | R1005 | D1003H | LUSC | 1 | I1056 | D1054H | OV | 1 | D1014 | D1014H | OV | 1 | D1014 | P1015R | SKCM | 1 | D1071 | R1072L | STAD | 1 | F992 | F992L | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for ATAD2 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | E1017 | E1017K | -1.3733934 | D1020 | D1020H | -1.1382667 | A1080 | R1082T | -1.0689562 | T1084 | R1082T | -1.0689562 | I1056 | D1054H | -1.0505786 | F992 | F992L | -1.0175282 | D1014 | P1015R | -0.99817843 | R1005 | D1003H | -0.75477621 | D1014 | D1014H | -0.74931551 | D1014 | D1014N | -0.74596632 | D1071 | R1072L | -0.37894701 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for ATAD2 |
![]() |
![]() |
Top |
Top |
Phenotype information for ATAD2 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C0017661 | Glomerulonephritis, IGA | 1 | Biomarker |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for ATAD2 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 38T | 5-METHYLURIDINE | 4qsw | A | D1014 E1017 | 37N | 3-(3,5-DIMETHYL-1,2-OXAZOL-4-YL)-5-[(PHENYLSULFONYL) AMINO]BENZOIC ACID | 4tu4 | A | D1014 E1017 | NP8 | 5-(5-METHOXYPYRIDIN-3-YL)-3-METHYL-8- [(PIPERIDIN-4-YL)AMINO]-1,2-DIHYDRO-1,7-NAPHTHYRIDIN- 2-ONE | 5a5r | A | D1014 E1017 D1071 | YD3 | 8-[[(3R,4R)-3-[[1,1-BIS(OXIDANYLIDENE)THIAN- 4-YL]METHOXY]PIPERIDIN-4-YL]AMINO]-3-METHYL-5- (5-METHYLPYRIDIN-3-YL)-1H-QUINOLIN-2-ONE | 5a83 | A | D1014 E1017 D1071 | III | Peptide ligand (ARG,GLY,LYS,GLY,GLY) | 4quu | A | D1020 D1071 | III | Peptide ligand (SER,GLY,ARG,GLY,ALY,GLY) | 4tt2 | A | D1020 D1071 | III | Peptide ligand (GLY,LEU,GLY,LYS,GLY) | 4qut | A | D1071 | JTF | 8-{[2-(DIMETHYLAMINO)ETHYL]AMINO}-3-METHYL-1, 2-DIHYDROQUINOLIN-2-ONE | 5a5p | A | D1071 | 78J | (3R,4R)-3-(CYCLOHEXYLMETHOXY)PIPERIDIN-4-YL] AMINO}-3-METHYL-1,2-DIHYDRO-1,7-NAPHTHYRIDIN- 2-ONE | 5a81 | A | D1071 | THM | THYMIDINE | 4qsv | A | E1017 | 6XC | 3-METHYL-8-[(PIPERIDIN-4-YL)AMINO]-1,2- DIHYDRO-1,7-NAPHTHYRIDIN-2-ONE | 5a5q | A | E1017 D1071 | YEJ | 8-[[(3R,4R)-3-[[1,1-BIS(OXIDANYLIDENE)THIAN- 4-YL]METHOXY]PIPERIDIN-4-YL]AMINO]-3-METHYL- 1H-1,7-NAPHTHYRIDIN-2-ONE | 5a82 | A | E1017 D1071 | MPD | 2-METHYLPENTANE-2,4-DIOL | 4qss | A | F992 | 39R | 3-(5-PHENYL-4H-1,2,4-TRIAZOL-3-YL)ANILINE | 4tz2 | A | I1056 | ALY | N(6)-ACETYL-L-LYSINE | 4tt4 | B | R1005 A1080 T1084 | III | Peptide ligand (SER,THR,GLY,GLY) | 4tt4 | B | T1084 |
Top |
Conservation information for LBS of ATAD2 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |